|
Myocardial Infarction
|
0.240 |
Biomarker
|
disease |
BEFREE |
Three randomized control trials (Canagliflozin Cardiovascular Assessment Study, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients [EMPA-REG OUTCOME], and Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 [DECLARE-TIMI 58]) showed that the sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally developed as glucose-lowering drugs, are associated with a lower rate of adverse renal outcomes, such as need for renal replacement therapy, doubling of serum creatinine, and loss of glomerular filtration rate (GFR) compared to those in placebo groups.
|
30939483 |
2019 |
|
Myocardial Infarction
|
0.240 |
Biomarker
|
disease |
BEFREE |
Reg proteins direct accumulation of functionally distinct macrophage subsets after myocardial infarction.
|
29850784 |
2018 |
|
Myocardial Infarction
|
0.240 |
GeneticVariation
|
disease |
BEFREE |
Long-term outcome data are available only for empagliflozin: in the EMPA-REG OUTCOME study, empagliflozin demonstrated reduced risk of the composite end-point of 3-point major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke), primarily because of a significant reduction in cardiovascular mortality.
|
28440009 |
2017 |
|
Stomach Neoplasms
|
0.240 |
PosttranslationalModification
|
group |
LHGDN |
REG Ialpha protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells.
|
18024479 |
2008 |
|
Myocardial Infarction
|
0.240 |
Biomarker
|
disease |
RGD |
Furthermore, Western blot analysis showed the corresponding pattern of Reg protein secretion into the serum after loading, and circulating levels of the protein after myocardial infarction were higher than those after aortic constriction.
|
15778284 |
2005 |
|
Myocardial Infarction
|
0.240 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, Western blot analysis showed the corresponding pattern of Reg protein secretion into the serum after loading, and circulating levels of the protein after myocardial infarction were higher than those after aortic constriction.
|
15778284 |
2005 |
|
Stomach Neoplasms
|
0.240 |
AlteredExpression
|
group |
LHGDN |
REG Ialpha protein may function as a trophic and/or anti-apoptotic factor in the development of gastric cancer.
|
15765400 |
2005 |
|
Stomach Neoplasms
|
0.240 |
Therapeutic
|
group |
CTD_mouse |
Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
|
15940630 |
2005 |
|
Stomach Neoplasms
|
0.240 |
Biomarker
|
group |
LHGDN |
Expression of reg I alpha protein in human gastric cancers.
|
15166487 |
2004 |
|
Stomach Neoplasms
|
0.240 |
AlteredExpression
|
group |
LHGDN |
REG gene expression is associated with the infiltrating growth of gastric carcinoma.
|
14508825 |
2003 |
|
Malignant neoplasm of stomach
|
0.230 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we found that the epigenetic methylation suppressed the expression level of REG1A in GC, and REG1A overexpression could suppress the phosphorylation of Akt or GSK3β signaling.
|
29222406 |
2017 |
|
Malignant neoplasm of stomach
|
0.230 |
GeneticVariation
|
disease |
BEFREE |
The data suggested that alterations in the CDC14A and MTMR3 genes may play a role in the development of GC and CRC with MSI-H by deregulating phosphatase functions possibly together with mutations of classical PTP genes.
|
20477815 |
2010 |
|
Malignant neoplasm of stomach
|
0.230 |
Therapeutic
|
disease |
CTD_mouse |
Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
|
15940630 |
2005 |
|
Malignant neoplasm of stomach
|
0.230 |
Biomarker
|
disease |
BEFREE |
Reg I alpha protein may play a role in the development of gastric cancers.
|
15166487 |
2004 |
|
Pancreatitis, Chronic
|
0.220 |
Biomarker
|
disease |
BEFREE |
There are two major hypotheses about the pathogenesis of chronic pancreatitis known as the "necrosis-fibrosis" and "pancreatic stone protein" hypotheses.
|
17238030 |
2007 |
|
Pancreatitis, Chronic
|
0.220 |
Biomarker
|
disease |
RGD |
Secretory apparatus assessed by analysis of pancreatic secretory stress protein expression in a rat model of chronic pancreatitis.
|
12764608 |
2003 |
|
Pancreatitis, Chronic
|
0.220 |
GeneticVariation
|
disease |
BEFREE |
We therefore investigated the possibility that alterations in the PSP gene might explain the chronic pancreatitis seen in this patient.
|
8482198 |
1993 |
|
Malignant tumor of colon
|
0.210 |
Biomarker
|
disease |
BEFREE |
Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi.
|
18183590 |
2008 |
|
Malignant tumor of colon
|
0.210 |
Biomarker
|
disease |
RGD |
Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene.
|
2332435 |
1990 |
|
Metabolic Syndrome X
|
0.200 |
Therapeutic
|
disease |
RGD |
The expression of intestinal REG (regenerating) family proteins which are widely involved in inflammatory bowel disease and diabetes are still unknown in metabolic syndrome.
|
21685239 |
2011 |
|
Hereditary Diffuse Gastric Cancer
|
0.200 |
Therapeutic
|
disease |
CTD_mouse |
Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
|
15940630 |
2005 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Increased expression of a regenerating (reg) gene protein in neonatal rat pancreas treated with streptozotocin.
|
8574288 |
1995 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Therapeutic
|
disease |
RGD |
Pancreatic beta-cell replication and amelioration of surgical diabetes by Reg protein.
|
8170952 |
1994 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sodium-glucose co-transporter (SGLT)-2 inhibitors have been shown to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in patients with type 2 diabetes mellitus (DM) and high cardiovascular risk in two large clinical outcome trials: empagliflozin in EMPA-REG OUTCOME and canagliflozin in CANVAS.
|
31747132 |
2020 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
|
31820559 |
2020 |